HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

der to reduce the incidence and severity of infusion-related adverse events. Patients also received prophylactic anti-infective treatment to reduce the risk of opportunistic infections. The primary endpoint for this trial was overall response rate (complete and partial response), and the study objective was to demonstrate a major response rate of at least 20 percent. Response rate was assessed by an independent review panel in accordance with the National Cancer Institute's guidelines for the diagnosis and treatment of CLL.

Of 93 evaluable patients, 31 demonstrated an objective response to treatment, for an overall response rate of 33%. Two of these responses were complete (2%) and 29 were partial responses (31%). Another 55 (59%) patients had disease stabilization. Median survival time has not yet been reached at about 10 months after the last patient was enrolled.

The safety profile of CAMPATH was consistent with that seen in previous studies and was judged by the investigators to be acceptable in this group of endstage CLL patients.

Adverse effects associated with CAMPATH in this study of 93 patients were mostly mild to moderate infusion-related symptoms. Severe (grade 3 and 4) infusion-related symptoms included: fever (13%), rigors (11%), dyspnea (6%), and hypotension (1%). During the study patients developed severe (grade 3 and 4) thrombocytopenia (low platelet count, 51%) or neutropenia (low white blood cell count, 61%) that usually improved within two months post-therapy. Some patients entering the study with severe (grade 3 and 4) thrombocytopenia and neutropenia improved to grade 2 or better within two months post-therapy: thrombocytopenia -- 7 of 19 (37%) patients improved,neutropenia -- 11 of 17 (65%) patients improved.

No unexpected serious adverse events were reported. The incidence of serious infections was reported to be 20% on this trial. It should be noted that infection is a common complication and cause of death
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2019)... JOSE, Calif. (PRWEB) , ... May 23, 2019 , ... ... IP Cores seamlessly integrated with its MIPI C-PHY v.1.2 IP supporting speeds of ... lane) and D-PHY v2.0 supporting speeds of upto 4.5 Gbps data rate per lane. ...
(Date:5/23/2019)... ... May 23, 2019 , ... Medicaid helps fill ... according to a new report by the Georgetown University Center for Children and ... rates for women of childbearing age and larger reductions in maternal deaths and ...
(Date:5/23/2019)... ... May 23, 2019 , ... Join Dr. Ashok Srivastava, CEO ... Vice President of Data Sciences at OmniComm Systems, Inc. , in a ... BST/UK) to learn about the benefits of visual patient profiles. Together, the two speakers ...
(Date:5/23/2019)... ... May 23, 2019 , ... Security ... technology to make software secure, is proud to announce that they have been ... received this honor after a thorough and independent analysis conducted by Great Place ...
(Date:5/23/2019)... ... May 23, 2019 , ... Embark ... joining forces to turn the tide in the rising rates of adolescent anxiety, ... Embark’s commitment to community, outpatient, and home-based care. Potomac’s national services will intervene ...
Breaking Medicine News(10 mins):
(Date:5/24/2019)... ... ... Amare Global is a finalist in two categories in the NutraIngredients-USA ... (Amare Global) and Probiotic Product of the Year ( Amare’s Kids FundaMentals ). ... on the emerging science of the microbiome and the gut-brain axis is not just ...
(Date:5/23/2019)... ... 2019 , ... More than 20 trauma survivors and their families gathered at ... responders and community partners. The theme for the program called “Firearm, Injury Prevention Every ... their support and stories, continue healing and say thank you to their caregivers. The ...
(Date:5/23/2019)... ... May 23, 2019 , ... ... arterial hypertension (PAH), today announced the presentation of positive data from a multi-center ... pulmonary arterial hypertension (PAH) who are on a stable regimen of dual-oral combination ...
Breaking Medicine Technology:
Cached News: